PATENT CLAIM ANALYSIS

Application Number: 16091438
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-05
Patent Classification: ["514", "264100"]

Abstract:
The present invention relates to the use of an MAPK signaling pathway inhibitor in the manufacture of a medicament for delaying the degeneration of dopaminergic neurons, in particular to the use in the manufacture of a medicament for treating PD. The MAPK signaling pathway inhibitor of the present invention can effectively delay the degenerative death of dopaminergic neurons and thus can fundamentally achieve the effect of treating PD. According to the present invention, the MAPK signaling pathway inhibitor is prepared into an oral dosage form and thus it does not need to be injected. The therapeutic effect on a patient can be achieved only by oral administration. According to the present invention, the MAPK signaling pathway inhibitor has a better therapeutic effect on PD caused by various causes and is of great significance for the treatment and cure of PD.

Claim (Index 12):
An MAPK signaling pathway inhibitor for the treatment of Parkinson's Disease (PD).

Metadata:
- Claim Count in Document: 18.0
- Percentile: 97.0
- Lexical Diversity: 2.24242
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15897138', '14119906', '15678432', '11572397', '11479173']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7679630583999091
- 35 USC 102 Novelty (BERT): 0.5162497692007987
- Combined Prediction Score: 0.742791729479998
- Mean Citation Score: 219.573934
- Max Citation Score: 237.44824
- Similarity Product: 131.78381735741615

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test